Ticker Details
Supernus Pharmaceuticals, Inc. Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders.
IPO Date:	May 1, 2012
Sector:	Healthcare
Industry:	Drug Manufacturers
Market Cap:	$2.8B
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$0.48 | 1.98%
Avg Daily Range (30 D):	$0.80 | 1.59%
Avg Daily Range (90 D):	$0.70 | 1.39%

Institutional Daily Volume
Avg Daily Volume:	.48M
Avg Daily Volume (30 D):	.5M
Avg Daily Volume (90 D):	.54M

Trade Size
Avg Trade Size (Sh.):	86
Avg Trade Size (Sh.) (30 D):	50
Avg Trade Size (Sh.) (90 D):	50

Institutional Trades
Total Institutional Trades:	4,795
Avg Institutional Trade:	$1.84M
Avg Institutional Trade (30 D):	$3.24M
Avg Institutional Trade (90 D):	$3.27M
Avg Institutional Trade Volume:	.06M
Avg Institutional Trades (Per Day):	1

Market Closing Trades
Avg Closing Trade:	$2.27M
Avg Closing Trade (30 D):	$5.61M
Avg Closing Trade (90 D):	$5.73M
Avg Closing Volume:	68.25K

News

May 6, 2026 @ 9:00 PM Supernus Pharmaceuticals to Participate in the Ban... Source: Na

Feb 23, 2026 @ 11:15 PM Supernus Pharmaceuticals to Participate in March I... Source: Na

Dec 16, 2025 @ 4:35 AM Supernus Stock Is Up 31% This Past Year but Still ... Source: Jonathan Ponciano

Jul 28, 2025 @ 12:25 PM Supernus Pharmaceuticals Announces Expiration of H... Source: Globe Newswire

Feb 11, 2025 @ 9:30 PM Supernus Pharmaceuticals to Host Conference Call a... Source: N/A

Financials
	TTM	Q1 2026	Q4 2025
Basic EPS	$-.51	$-.04	$-.07
Diluted EPS	$-.51	$-.04	$-.07
Revenue	$776.83M	$207.71M	$211.57M
Gross Profit	$694.64M	$184.31M	$188.57M
Net Income / Loss	$-29.02M	$-2.29M	$-4.11M
Operating Income / Loss	$-60.36M	$-8.33M	$-3.94M
Cost of Revenue	$82.19M	$23.39M	$23.01M
Net Cash Flow	$70.47M	$56.42M	$-22.92M
PE Ratio